Study Objectives: This prospective observational study was designed to systematically examine the effect of subthalamic deep brain stimulation (DBS) on subjective and objective sleep-wake parameters in Parkinson patients. Methods: In 50 consecutive Parkinson patients undergoing subthalamic DBS, we assessed motor symptoms, medication, the position of DBS electrodes within the subthalamic nucleus (STN), subjective sleep-wake parameters, 2-week actigraphy, video-polysomnography studies, and sleep electroencepahalogram frequency and dynamics analyses before and 6 months after surgery. Results: Subthalamic DBS improved not only motor symptoms and reduced daily intake of dopaminergic agents but also enhanced subjective sleep quality and reduced sleepiness (Epworth Sleepiness Scale: −2.1 ± 3.8, p < .001). Actigraphy recordings revealed longer bedtimes (+1:06 ± 0:51 hours, p < .001) without shifting of circadian timing. Upon polysomnography, we observed an increase in sleep efficiency (+5.2 ± 17.6%, p = .005) and deep sleep (+11.2 ± 32.2 min, p = .017) and increased accumulation of slow-wave activity over the night (+41.0 ± 80.0%, p = .005). Rapid eye movement sleep features were refractory to subthalamic DBS, and the dynamics of sleep as assessed by state space analyses did not normalize. Increased sleep efficiency was associated with active electrode contact localization more distant from the ventral margin of the left subthalamic nucleus. Conclusion: Subthalamic DBS deepens and consolidates nocturnal sleep and improves daytime wakefulness in Parkinson patients, but several outcomes suggest that it does not normalize sleep. It remains elusive whether modulated activity in the STN directly contributes to changes in sleep-wake behavior, but dorsal positioning of electrodes within the STN is linked to improved sleep-wake outcomes.
INTRODUCTION
Sleep-wake disturbances affect up to 80%-90% of patients with Parkinson's disease (PD), and often significantly impair quality of life. 1 Nonconsolidated sleep with frequent awakenings, rapid eye movement (REM) sleep behavior disorder (RBD) with enactment of vivid dreams, and excessive daytime sleepiness are frequent complaints of PD patients. Polysomnography (PSG) findings in PD patients include decreased sleep efficiency, reduced total sleep time, impaired slow-wave activity, and rarefied REM sleep compared to healthy controls. 2 Deep brain stimulation (DBS) in the subthalamic nucleus (STN) is a gold standard treatment for PD patients suffering from motor fluctuations or pharmacotherapy-refractory tremor. There is some evidence that STN stimulation may affect and even improve sleep-wake functions. In studies examining subjective sleep quality after subthalamic stimulation, overall sleep quality and total sleep time improved after STN-DBS. [3] [4] [5] To date, most studies including objective PSG measures have been small case series, with different patient populations, study protocols, various assessment time points, and electrode settings: Arnulf and colleagues evaluated 10 insomniac PD patients 3 to 6 months after STN-DBS and found stimulation to increase total sleep time and sleep efficiency. 6 Similar findings have been made by Monaca et al. in 10 patients before STN-DBS and again after 3 months, 7 by Cicolin and colleagues in 5 patients before and 3 months after bilateral STN-DBS electrode implantation, 8 and by Merlino et al. in 15 patients 1 week before and after microsubthalamotomy. 9 On the other hand, Iranzo and colleagues evaluated 11 PD patients before and 6 months after bilateral STN-DBS implantation, but stimulation did not increase sleep efficiency. 10 In all these studies, REM sleep and REM sleep-related motor outcomes seemed to be mostly unchanged by STN-DBS. However, Nishida and colleagues examined sleep in 10 PD patients 1 week before and 1 week after implantation of either unilateral or bilateral STN-DBS electrodes and found increased REM sleep duration and in 1 patient even resolution of RBD. 11 There are also conflicting data on the effects of STN-DBS on restless legs syndrome (RLS) and periodic limbs movements, with some studies showing improvement 12, 13 and others reporting deterioration in RLS on STN-DBS. 14, 15 Thus, given the fact that many confounding factors are likely to influence these results, such as age, dopaminergic medication, disease duration, the type of PD, motor outcome of DBS, and exact electrode placement, larger electrophysiological studies are needed to reliably analyze the impact of STN-DBS on sleep-wake regulation. Here, we studied sleep-wake behavior with subjective assessments, 2-week actigraphy, and
Statement of Significance
Sleep-wake disturbances are most frequent in Parkinson patients, but there is no larger systematic study to objectively examine the impact of subthalamic deep brain stimulation (DBS) on sleep in Parkinson patients. This study was designed to close this gap by prospectively applying electrophysiological examinations in 50 Parkinson patients. Subthalamic DBS improves sleep continuity, deepens sleep, increases accumulated slow-wave activity, and improves excessive daytime sleepiness. However, the dynamics of sleep did not normalize. Dorsal placement of the active electrode increases the likelihood of a beneficial sleep effect. Whether this observation is due to a sleep-modulating effect of the subthalamic nucleus itself-a nucleus neighboring and connecting to multiple sleep-wake active neuronal areas-remains elusive, but this finding will guide future exploration.
nocturnal PSG in 50 PD patients before and 6 months after subthalamic DBS.
METHODS
This is an observational controlled trial to examine effects of STN-DBS on sleep-wake behavior in PD. The study protocol was approved by the local ethics committee (KEK Zurich), and written informed consent was given by participating patients.
Patients
We included 50 consecutive PD patients who were treated with bilateral STN-DBS. The first patient was recruited in January 2011, and the 50th patient was enrolled in October 2014. All diagnoses were made according to international standard criteria. 16 After inclusion, we assigned 2 patient subgroups, akinetic-rigid (AR) and tremor-dominant (Tre) merged with mixed equivalent phenotype (Ae; Tre+Ae) based on expert judgment. 17 Quadripolar DBS leads (3389, Medtronic, Minneapolos, MN) were implanted in the STN in magnetic resonance (MR)-based frame-guided awake surgeries supported by intraoperative microelectrode recording and standardized intraoperative test stimulation. The leads were connected to an Activa® impulse generator (Medtronic). MR imaging, intraoperative recordings, and test stimulation were used for the determination of the margins of the STN and the related position of the active electrode contacts. Postoperatively, we adjusted DBS settings and medication according to the individual patients' needs over the first 6 postoperative months.
Clinical Assessments
All evaluations were performed twice, within 3.1 ± 3.6 months prior to surgery (baseline) and 7.7 ± 2.8 months after implantation of DBS electrodes, that is, on medication alone and on stimulation in combination with medication.
We examined motor outcomes with part III of the Unified Parkinson's Disease Rating Scale (UPDRS). 18 As this study was not designed to measure motor outcome after STN-DBS, we did not ask patients to stop medication again for pure motor assessments. Therefore, all assessments with the UPDRS were performed in reasonably good ON conditions. Furthermore, we calculated total L-dopa equivalent dose (LED) along previous recommendations. 19 In all patients, we registered the intake of benzodiazepines and z-drugs, antidepressants, neuroleptics, and amantadine. Antidepressants were grouped into compounds with sedative or activating properties and mirtazapine with dosage-dependent effect.
All patients completed the Zurich sleep questionnaire. This questionnaire consists of items on sleep and sleep-wake disorders in general, sleep timing, questions on daytime complains, symptoms suggestive of sleep apnea, insomnia, parasomnia, narcolepsy features, restless legs syndrome, and mood, usually by implementing a 5-point Likert-type scale. Standardized self-rating questionnaires that have been validated in German, including the Epworth Sleepiness Scale (ESS) and the Fatigue Severity Scale (FSS), were also part of this questionnaire. 20, 21 An ESS score >10 indicated subjective excessive daytime sleepiness and an FSS score >4 indicated fatigue. In addition, all patients filled in a sleep log during actigraphy recordings which includes bed time, getup time, and notes about special events during the night and/or day. The presence of RLS was defined according to the International Restless Legs Syndrome Study Group (IRLSSG) criteria. 22 RLS diagnosis was made when all the 4 criteria were met.
Electrophysiological Assessments
All patients completed 2-week rest-activity recordings at home and without scheduled restrictions to their sleep-wake behavior. To this end, we applied Actiwatch (Actiwatch AW2, Phillips-Respironics, OR), which was worn on the nondominant arm, that is, regardless of the side that was more affected by PD. We excluded days and nights with missing data and the first and the last day of the activity monitoring, as daytime restactivity patterns were incomplete. Furthermore, we excluded the night spent in the sleep laboratory, as bedtime and sleep duration were not freely chosen by the patient. On average, 13.5 ± 2.1 days and 14.0 ± 2.2 nights of actigraphic data per patient were analyzed.
Keeping in mind that PD patients can express marked movements during sleep (e.g., RBD), but on the other hand may appear resting during daytime hypokinesia, we chose a conservative approach when analyzing actigraphy data. We extracted the following measures for each subject using the standard software (Actiware version 6): Going-to-bed times and get-up times were identified automatically by the algorithm, then if needed manually adjusted by using information, first from markers when patients' pressing a button when going to bed and switching out the bed light and getting up in the morning, second from sleep logs, third from light data, and forth from rest-activity pattern in hierarchical order. We calculated night rest duration, that is, interval between going-to-bed and get-up time and midpoint rest time, also known as midsleep time as an internal circadian time marker. 23 We calculated daytime activity, for example, averaged activity counts from leaving the bed in the morning till going to bed at night, as a measure of general daily activity. Additionally, we calculated activity during the rest episode at night, total moving time at night as scored mobile time during the rest episode, the movement bout-index, for example, the number of continuous blocks with each epoch scored as mobile relative to the rest episode duration, and the average duration of immobile bouts between movement bouts. During data acquisition, medication was taken as needed but kept constant within each condition. The postsurgical rest-activity recording was performed under continuous 24 hours constant STN-DBS stimulation in combination with medication.
We performed PSG recordings with digital videography (Embla N7000, RemLogic v3.2) according to AASM standard criteria and as introduced before. 24, 25 Two experienced sleep specialists (EW and HBV) scored and rescored all recordings.
Time in bed (TIB) of the 2 PSGs within the same subject was not identical. To avoid that sleep changes might only be due to differences in TIB, we adjusted TIB artificially for data analysis by matching the PSG length. Thus, the total time analyzed was identical for both the conditions.
As sleep stage scoring can be difficult in Parkinson patients, 26 we made additional standardized considerations for assigning sleep stages in difficult cases. We compared presumed sleep patterns with patterns of definite wake periods. We defined sleep period time as the time from sleep onset to lights on. Sleep onset, sleep latency, sleep efficiency as the ratio of the total sleep time divided by sleep period time, REM sleep latency, wake time after sleep onset (WASO), periodic limb movements during sleep (PLMS), arousal index, and respiratory events including the apnea-hypopnea index (AHI) were also assessed. 24 To calculate a quantitative measure of sleep fragmentation, we assessed the number of awakenings per hour of sleep and the number of longer awakenings (>5 min, >15 min, and >30 min).
RBD was evaluated by history-taking, by video-PSG information, and by quantification of EMG activity during REM sleep. We applied the Sleep INsbruck BARcelona (SINBAR) EMG montage to detect REM sleep phasic and tonic EMG activity. 27 According to Frauscher and colleagues, an REM sleep without atonia (RWA) index above 32 indicates the presence of REM sleep without atonia and therefore RBD.
Preprocessing of the EEG signal for further analysis included rereferencing the EEG to linked mastoid reference (for reducing electrocardiogram and other artifacts), filtering (0.5 Hz high-pass and 40 Hz low-pass filter), and artifact identification on basis of a 5-s semiautomatic procedure based on power in the 0.75-4.5 Hz and 20-40 Hz bands and visual inspection. 28 Artifact-free 5-s EEG spectra were collapsed and matched with the corresponding sleep stage scores when at least four of six 5-s epochs were artifact-free otherwise the whole 30-s epoch was rejected for further spectral analysis. Absolute-all-night power spectra were computed for NREM sleep (N1, N2, N3 for the two central derivations). The EEG power during NREM sleep from 0.5 to 4.5 Hz was defined as slow-wave activity (SWA). Furthermore, we assessed slow-wave energy (SWE), a measure of dissipation of sleep pressure, as the cumulative sum of SWA during NREM sleep. 29 To show the progression of mean SWE over time, total time analyzed of each single night was divided into 10 equal time bins and SWA was first averaged within each bin before accumulation over the whole night was calculated. Thus, we were able to visualize the time course of rising mean SWE from lights off till lights on despite the variability of total time analyzed of each patient.
Additionally, we performed state space modeling of spectral sleep EEG data as described earlier. 30 In short, we determined the frequency ratios of 2 selected frequency bands, and we used the distribution of frequency ratios in a 2-dimensional space (specification and more detail see 30 ). As a measure of dynamic properties of sleep, we calculated velocities in state space as the distance between 2 subsequent states divided by the time interval between these states. 
RESULTS
We studied 50 PD patients with a mean age of 61 ± 10 years, mean disease duration of 12 ± 5 years, mean presurgical on-medication Hoehn and Yahr stage of 2.3 ± 0.6 (median: 2, min/max: 1/3), and mean presurgical on-medication UPDRS part III motor score of 25 ± 10 ( Table 1) . Before surgery, 54% reported sleep maintenance insomnia. Fatigue (FSS > 4) was present in 55% of patients and excessive daytime sleepiness (ESS > 10) in 44%. Ten of 50 patients were on sedative medication. Five of 50 patients fulfilled the IRLSSG criteria of RLS.
STN-DBS effects on motor symptoms can be found in Table  2 . On STN-DBS, motor symptoms on treatment were reduced by 35% (UPDRS part III) and total dopaminergic medication (LED total) by 61%. Figure 1A ). On DBS, only 1 of 5 five patients with RLS still fulfilled the IRLSSG criteria of RLS.
Two weeks of rest-activity recordings with standard actigraphy confirmed longer bed times ( Figure 1B) : On DBS, patients went significantly earlier to bed and stayed longer in bed in the morning, resulting in a longer nighttime rest (BL: 7:02 ± 1:06 hr; on DBS: 8:08 ± 0:43 hr, paired t-test, p < .001, within-patient difference +1:06 ± 0:51 hr, p = .005). "Midpoint rest time" was similar, indicating stable circadian timing (BL: 03:00 ± 00:49; DBS: 03:05 ± 00:53 o'clock, paired t-test, p = .326). Motor activity during the rest episode was similar preand on DBS with respect to activity (BL: 29 ± 26; DBS: 27 ± 19, Wilcoxon signed ranks test, p = .781), total moving time (BL: 119 ± 57 min; DBS: 120 ± 52 min; Wilcoxon signed ranks test, p = .546), movement bout-index (BL: 6.0 ± 1.9 /h; DBS; 6.4 ± 1.4 /h; paired t-test, p = .099), and the average immobility duration between movement bouts (BL: 9.4 ± 7.0 min, DBS: 7.8 ± 2.7min, Wilcoxon signed ranks test, p = .412). On the other hand, daytime activity was significantly lower on DBS (drop of −16% ± 34%, BL: 298 ± 128; DBS: 223 ± 84, paired t-test, p < .001); however, the decrease in activity did not differ between motor PD subtypes.
The PSG findings are given in Table 3 and Figure 1C -E. On DBS, we observed a significant within-patient difference increase in total sleep time (+21.2 ± 74.9 min, p = .016), sleep efficiency (+5.2 ± 17.6%, p = .005), and deep sleep (N3, +11.2 ± 32.2 min, p = .017), together with a reduction in WASO (−18.0 ± 58.6 min, p = .023) and shorter REM sleep latencies (−25.1 ± 89.5 min, p = .047). Sleep latency, the duration of N1, N2, and REM sleep were unchanged. Sleep fragmentation as assessed by awakening index and the number of longer awakenings was not altered on DBS (all Wilcoxon signed-rank test p > .05). Also, the number of body position changes during sleep was similar before and on DBS. Although deep sleep was increased, we could not identify a significant increase in SWA in our sample. However, accumulated SWA (=SWE) was significantly higher at the end of the DBS night (within-patient difference +41.0% ± 80.0%, p = .005; Figure 1C ). DBS had no impact on arousal index and AHI. On the other hand, PLMS indices almost doubled after surgery, but the prevalence of RLS remained unchanged (BL: 10%; DBS: 2%, McNemar test p = .125). The increase in PLMS was associated with the reduction in dopamine agonists ( Figure 1D ). STN-DBS had no impact on the RBD marker RWA (Table 3 ). The occurrence of RWA above the SINBAR cutoff was similar before and after surgery (BL: 65.9%, DBS: 64.4%, McNemar test: p = 1.000).
As a measure of dynamic properties of sleep, we calculated different parameters in state space. Both conditions showed well-defined clusters of sleep behavioral states (W, N2, N3, REM; Figure 2A and B). Despite the improvement in sleep efficiency and deep sleep, DBS did not increase state space velocity but tended to further slow down sleep-wake dynamics ( Figure 2C ). Distance between cluster centroids for each sleep stage were unaltered on DBS (all paired t-tests p > .05).
Finally, we aimed at identifying predictors for a beneficial sleep-wake outcome (Table 4) .
Increase in sleep efficiency was linked to higher UPDRS III reduction, that is, more marked motor improvement in DBS and a location of the active electrode pole more distant from the ventral margin of the STN. However, only the left stimulation electrode showed this specific effect (R = 0.413, p = .007; Figure 3 ). Same associations were found for total sleep time. There was no interaction effect of UPDRS III change and active electrode location for sleep efficiency and total sleep time (sleep efficiency: delta UPDRS III × left active electrode pole more distant from ventral margin of STN: b = 0.61; upper and lower confidence interval −0.016 and 1.38; p = .119; total sleep time similar result). This observation supports the notion that factors electrode location and motor improvement are independent. Absolute increase in deep sleep was only linked to higher reduction in LED. The model for SWE revealed 2 significant predictors, a higher reduction in dopaminergic medication and AR versus Tre+Ae phenotypes: PD patients with predominant AR features gain more SWE on DBS compared to preoperative sleep than pooled tremor and equivalence phenotypes ( Figure 1E ). Otherwise, the 2 groups of PD phenotypes did not differ in terms of age, disease duration and Hoehn&Yahr stage, reduction in UPDRS III, or total LED on STN-DBS. Finally, decreased WASO was linked to UPDRS III reduction and higher reduction in LED and again active electrode pole location more distant from the ventral STN margin. No significant model could be fitted for the increased longer rest duration (actiwatch data) and for the improvement in subjective daytime sleepiness (ESS).
DISCUSSION
This prospective study in 50 PD patients undergoing bilateral DBS in the STN revealed that stimulation-particularly in a dorsal position within the STN-ameliorated nocturnal sleep and daytime Do the observations of deeper and more consolidated sleep on STN-DBS indicate that stimulation normalizes sleep in PD patients? Although this study was not designed to find out whether DBS reinstates normal sleep-as we did not include a matched control group-some of its outcomes suggest that STN-DBS does not normalize sleep. First and foremost, we previously found decreased sleep-wake dynamics in PD patients compared to healthy controls as assessed by quantitative analysis of state space velocity. 31 State space velocity can be interpreted as a measure for sleep state instability. On DBS, state space velocity became slower thus did not normalize. Second, the occurrence of RBD was unchanged in regard to subjective complains, videographical assessments, and amount of RWA. Third, PLMS became even more increased after DBS.
The finding of increased PLMS on DBS was linked to the reduction in dopamine agonists; however, arousals from sleep did not increase, and therefore the clinical relevance seems questionable. In case of a history of RLS symptoms in a DBStreated PD patient, however, treating physicians may want considering to continue treatment with dopamine agonists, as their reduction may not only be associated with apathy but also with enhanced periodic limb movements during sleep. 34 Current evidence on the impact of STN-DBS on comorbid RLS in Parkinson patients is conflicting, 13, 15 but in our study, the prevalence of RLS symptoms remained unchanged.
Another question is whether or not subthalamic stimulation directly impacts sleep-wake behavior or whether improved sleep results from better nocturnal motor control. More consolidated sleep, that is, higher sleep efficiency, decreased WASO, and increased total sleep time during PSG, was associated with active left electrode contacts more distant from the ventral STN margins. On the contralateral side, similar findings were not found. Therefore and although asymmetric properties of nonmotor medioventral segments of the STN have been proposed, the link between active electrode contacts and sleep consolidation must be discussed with utmost caution. 35 The hypothesis that maximized dorsolateral location of active electrode contacts-which is known to provide best motor effects-leads to improved sleep because of better nocturnal motor relief cannot be dismissed. 36 On the other hand, the number of body position changes during sleep was similar before and on DBS in the present study.
Still, the STN might play a role in sleep-wake regulation. Although this small nucleus is classically considered a relay of the indirect basal ganglia motor pathway, its connections exceed the motoric circuits. 37 The nucleus is located at the diencephalo-mesencephalic junction, posterolateral to the hypothalamus, and medial to the substantia nigra and red nucleus. 37 The STN is thus not far away from wake-promoting midbrain areas. 38, 39 The nucleus has inhibitory connections to the anterior hypothalamus and the upper part of the mesencephalic reticular substance, 40 and glutamatergic innervations to the substantia nigra pars compacta which in turn innervate several brain areas involved in sleep regulation. 41 It has important reciprocal connections with the wake-and REM-modulating pedunculopontine tegmental nucleus (PPN). 42, 43 The anterior STN projects to the basolateral amygdala and ventral-anterior thalamus 37 with the ventral and lateral thalamic relay nuclei possibly playing a role in producing wakefulness. 
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